Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pharmacokinetics"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 8393
Tytuł:
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
Autorzy:
Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.
Parrott N; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Peck RW; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Hope W; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 464-475. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Fosfomycin*/pharmacokinetics
Neonatal Sepsis*/drug therapy
Humans ; Infant, Newborn ; Amikacin/pharmacokinetics ; Anti-Bacterial Agents/pharmacokinetics ; Microbial Sensitivity Tests ; Multicenter Studies as Topic ; Clinical Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Autorzy:
Terrier J; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Gaspar F; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Gosselin P; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Raboud O; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Lenoir C; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Rollason V; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Csajka C; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Samer C; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Fontana P; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Angiology and Haemostasis, Geneva University Hospitals, Geneva, Switzerland.
Daali Y; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Reny JL; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pokaż więcej
Corporate Authors:
OptimAT study group
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1872-1883. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Rivaroxaban*/pharmacokinetics
Pyrazoles*/pharmacokinetics
Humans ; Aged ; Pyridones/pharmacokinetics ; Administration, Oral ; Anticoagulants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Interspecies and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin.
Autorzy:
Catozzi S; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.
Hill R; EPSRC and MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, UK.
Li XM; UPR 'Chronotherapy, Cancers and Transplantation,' Faculty of Medicine, Université Paris-Saclay, Villejuif, France.
Dulong S; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.; UPR 'Chronotherapy, Cancers and Transplantation,' Faculty of Medicine, Université Paris-Saclay, Villejuif, France.
Collard E; CEA, CNRS, NIMBE, Université Paris-Saclay, Gif-sur-Yvette, France.
Ballesta A; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Feb; Vol. 12 (2), pp. 221-235. Date of Electronic Publication: 2022 Dec 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacokinetics
Humans ; Rats ; Mice ; Animals ; Oxaliplatin ; Models, Biological ; Pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.
Autorzy:
Leung E; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Cottrell ML; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Sykes C; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
White N; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Kashuba ADM; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Dumond JB; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1922-1930. Date of Electronic Publication: 2023 Oct 09.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents*/pharmacokinetics
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Female ; Humans ; Tenofovir/pharmacokinetics ; Emtricitabine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Autorzy:
Gaspar F; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Terrier J; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Favre S; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Gosselin P; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Fontana P; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Angiology and Haemostasis, Geneva University Hospitals, Geneva, Switzerland.
Daali Y; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Lenoir C; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Samer CF; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Rollason V; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Reny JL; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Csajka C; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Guidi M; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Oct; Vol. 12 (10), pp. 1541-1552. Date of Electronic Publication: 2023 Sep 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Biological*
Pyridones*/pharmacokinetics
Humans ; Pyrazoles/pharmacokinetics ; Area Under Curve
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).
Autorzy:
van Wijk RC; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Imperial MZ; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Savic RM; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Solans BP; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Sep; Vol. 12 (9), pp. 1187-1200. Date of Electronic Publication: 2023 Jun 11.
Typ publikacji:
Journal Article
MeSH Terms:
Databases, Factual*
Pharmacokinetics*
Meta-Analysis as Topic*
Humans ; Drug Development
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Autorzy:
Chala A; Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.
Kitabi EN; Division of Pharmacometrics, Office of Clinical Pharmacology, Food and Drugs Administration, Silver Spring, Maryland, USA.
Ahmed JH; Department of Pharmacy, Jimma University, Jimma, Ethiopia.
Tadesse BT; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.; Department of Pediatrics, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
Chaka TE; Department of Pediatrics and Child Health, Adama Hospital Medical College, Adama, Ethiopia.
Makonnen E; Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Aklillu E; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jun; Vol. 12 (6), pp. 783-794. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/pharmacokinetics
HIV Infections*/drug therapy
HIV Infections*/genetics
Humans ; Child ; Cytochrome P-450 CYP2B6/genetics ; Ethiopia ; Benzoxazines/therapeutic use ; Benzoxazines/pharmacokinetics ; Cyclopropanes ; Body Weight ; Genotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Autorzy:
Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.
Rafizadeh R; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
Polasek TM; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; Certara, Princeton, New Jersey, USA.; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Bousman CA; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research (CAPKR), School of Health Sciences, University of Manchester, Manchester, UK.; Simcyp Division, Certara UK Limited, Sheffield, UK.
Stowe R; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.; Djavid Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Neurology (Medicine), University of British Columbia, Vancouver, British Columbia, Canada.
Carrion P; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Sheffield LJ; MyDNA Life Australia Limited, Victoria, Australia.
Kirkpatrick CMJ; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/pharmacokinetics
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacokinetics
Schizophrenia*/drug therapy
Humans ; Fluvoxamine ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Autorzy:
Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Ramsden D; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Zhang L; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Michon I; Certara, Sheffield, UK.
Leifke E; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Smith N; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Jones HM; Certara, Sheffield, UK.
Scarpignato C; United Campus of Malta, Msida, Malta.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Cytochrome P-450 CYP3A Inducers*/pharmacokinetics
Humans ; Midazolam/pharmacokinetics ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Models, Biological
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
Autorzy:
Liu Y; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Huyan X; The First Health Care Department, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
Zhang Q; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Qing H; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Zhang Q; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Wang X; Department of Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co, Ltd., Jiangsu, China.
Li Y; Department of Statistics and Programming, Jiangsu Hengrui Pharmaceuticals Co, Ltd., Jiangsu, China.
Liu Z; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Hu W; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Apr; Vol. 12 (4), pp. 376-384. Date of Electronic Publication: 2022 Nov 21.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Metformin*/pharmacokinetics
Diabetes Mellitus, Type 2*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*
Humans ; Hypoglycemic Agents/pharmacokinetics ; Healthy Volunteers ; Delayed-Action Preparations ; East Asian People ; Area Under Curve
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil.
Autorzy:
He Y; Department of Anesthesiology, Chinese PLA General Hospital, Beijing, China.
Qin M; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
Li M; Liaoning Institute for Drug Control, Shenyang, China.
Zhi D; Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education, Dalian Minzu University, Dalian, China.
Tian B; Department of Pharmacy, Binzhou Medical University, Yantai, China.
Qin F; Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Pokaż więcej
Źródło:
Chirality [Chirality] 2023 Apr; Vol. 35 (4), pp. 247-255. Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Flurbiprofen*/pharmacokinetics
Rats ; Animals ; Injections, Intravenous ; Stereoisomerism ; Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Use of physiologically-based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended-release nifedipine.
Autorzy:
Tan ML; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Gao Z; Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, Missouri, USA.
Babiskin A; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Kim MJ; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Fang L; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Zhang L; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Zhao L; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 247-256. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Nifedipine*/chemistry
Nifedipine*/pharmacokinetics
Omeprazole*/pharmacology
Humans ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Drug Liberation ; Administration, Oral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
Autorzy:
Lee L; PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Murase K; PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Ma J; PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Thoolen M; PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Mar; Vol. 12 (3), pp. 279-286. Date of Electronic Publication: 2022 Dec 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacokinetics
Breast Neoplasms*
Humans ; Female ; Rosuvastatin Calcium/pharmacokinetics ; Lipoxygenase Inhibitors ; ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics ; Arachidonate 15-Lipoxygenase/metabolism ; Neoplasm Proteins/metabolism ; Drug Interactions
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The influence of flip-flop in population pharmacokinetic analyses.
Autorzy:
Kuan IHS; School of Pharmacy, University of Otago, Dunedin, New Zealand.; Certara, Princeton, New Jersey, USA.; Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
Wright DFB; School of Pharmacy, University of Otago, Dunedin, New Zealand.
Duffull SB; School of Pharmacy, University of Otago, Dunedin, New Zealand.; Certara, Princeton, New Jersey, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Mar; Vol. 12 (3), pp. 285-287. Date of Electronic Publication: 2023 Jan 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pharmacokinetics*
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
Autorzy:
Svensson RJ; Pharmetheus AB, Uppsala, Sweden.
Ooi QX; Pharmetheus AB, Uppsala, Sweden.
Friberg LE; Pharmetheus AB, Uppsala, Sweden.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Maharaj N; Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
Reddy PK; Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
López-Lázaro L; Dr. Reddy's Laboratories SA, Basel, Switzerland.
Hansson E; Pharmetheus AB, Uppsala, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Feb; Vol. 12 (2), pp. 154-167. Date of Electronic Publication: 2022 Dec 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Biosimilar Pharmaceuticals*/pharmacokinetics
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Rituximab/pharmacokinetics ; Switzerland
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.
Autorzy:
Barth A; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Global Blood Therapeutics, San Francisco, California, USA.
Hossain M; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Servier Pharmaceuticals, Boston, Massachusetts, USA.
Perry CR; GSK, Collegeville, Pennsylvania, USA.
Gross AS; GSK R&D, Sydney, AU.
Ogura H; GSK, Tokyo, Japan.
Shabbir S; GSK, Stevenage, UK.
Thomas S; GSK, Collegeville, Pennsylvania, USA.
Dumont EF; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Boston Pharmaceuticals, Cambridge, Massachusetts, USA.
Brimhall DB; PPD, Las Vegas, Nevada, USA.
Srinivasan M; GSK, Collegeville, Pennsylvania, USA.
Swift B; GSK, Durham, North Carolina, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jan; Vol. 12 (1), pp. 38-56. Date of Electronic Publication: 2022 Dec 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Acenaphthenes*/pharmacokinetics
Heterocyclic Compounds, 3-Ring*/pharmacokinetics
Humans ; Healthy Volunteers ; Anti-Bacterial Agents/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?
Autorzy:
Yamazaki S; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, San Diego, California, USA.
Evers R; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
De Zwart L; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, Beerse, Belgium.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jan; Vol. 12 (1), pp. 8-12. Date of Electronic Publication: 2022 Nov 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Humans ; Rifampin/pharmacokinetics ; ATP Binding Cassette Transporter, Subfamily B ; Drug Interactions ; Models, Biological ; Cytochrome P-450 CYP3A Inducers/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers.
Autorzy:
Kim MJ; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim H; Department of Emergency Medical Services, College of Health Sciences, Eulji University, Seongnam, Republic of Korea.
Lee SM; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choi HY; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim YH; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choi SC; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim EH; Clinical Trial Center, Asan Medical Center, Seoul, Republic of Korea.
Park HJ; Clinical Trial Center, Asan Medical Center, Seoul, Republic of Korea.
Lim HS; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jan; Vol. 12 (1), pp. 21-29. Date of Electronic Publication: 2022 Oct 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Platelet Aggregation Inhibitors*/pharmacokinetics
Platelet Aggregation*
Adult ; Male ; Humans ; Prasugrel Hydrochloride/pharmacokinetics ; Platelet Function Tests ; Healthy Volunteers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Autorzy:
Sharma S; AstraZeneca, South San Francisco, California, USA.
Pepin X; New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, England, UK.
Burri H; AstraZeneca, South San Francisco, California, USA.
Zheng L; AstraZeneca, South San Francisco, California, USA.
Kuptsova-Clarkson N; AstraZeneca, Gaithersburg, Maryland, USA.
de Jong A; Acerta Pharma B.V., Oss, The Netherlands.
Yu T; AstraZeneca, South San Francisco, California, USA.
MacArthur HL; AstraZeneca, Mississauga, Ontario, Canada.
Majewski M; AstraZeneca, Mississauga, Ontario, Canada.
Byrd JC; Department of Internal Medicine and University of Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Furman RR; New York-Presbyterian/Weill Cornell Medicine, New York, New York, USA.
Ware JA; AstraZeneca, South San Francisco, California, USA.
Mann J; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, England, UK.
Ramies D; AstraZeneca, South San Francisco, California, USA.
Munugalavadla V; AstraZeneca, South San Francisco, California, USA.
Sheridan L; Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, England, UK.
Tomkinson H; AstraZeneca, Cambridge, England, UK.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1294-1307. Date of Electronic Publication: 2022 Aug 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Proton Pump Inhibitors*/adverse effects
Proton Pump Inhibitors*/pharmacokinetics
Pyrazines*/adverse effects
Pyrazines*/pharmacokinetics
Adult ; Humans ; Biological Availability ; Therapeutic Equivalency ; Tablets ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study.
Autorzy:
Liu H; Department of General Practice, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu H; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Sun L; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qiao J; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Li J; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tan H; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu Y; Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Aug; Vol. 11 (8), pp. 930-937. Date of Electronic Publication: 2022 Apr 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Blood Glucose*
Insulin*/pharmacokinetics
C-Peptide ; Cross-Over Studies ; Double-Blind Method ; Glucose ; Humans ; Hypoglycemic Agents/pharmacokinetics ; Insulin Aspart/pharmacokinetics ; Male ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 8393

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies